Why 5-Amino-1MQ Is Sold as a Capsule: Bioavailability Notes
What 5-amino-1MQ actually is
5-amino-1-methylquinolinium, usually shortened to 5-amino-1MQ, is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is a synthetic quinolinium salt, not a chain of amino acids, so it does not belong in the same category as injectable peptides like semaglutide or growth-hormone-releasing peptides. That distinction is the entire reason it is sold as a capsule instead of a vial and syringe, and it is worth being precise about before anything else on this page. For background on how NNMT inhibition is supposed to work, see the mechanism overview and the NAD metabolism explainer.
5-amino-1MQ has no FDA-approved use for any indication, is not on the FDA's 503A bulk drug substances list for compounding (FDA list), and human clinical trial data on its safety, dosing, or effectiveness are absent from the published record reviewed for this page. Anything below describes laboratory and animal findings, not confirmed human outcomes. For a fuller regulatory picture, see the FDA status page and the FDA Peptide Status Tracker.
Why peptides need injections and small molecules don't have to
Peptides are chains of amino acids held together by peptide bonds. Swallowed peptides meet stomach acid and digestive proteases that are specifically built to break peptide bonds apart, which is why most therapeutic peptides are injected rather than swallowed. 5-amino-1MQ is structurally nothing like that. It is a single small ring-based molecule with no peptide bonds for digestive enzymes to target, closer in class to a conventional drug-like small molecule than to a biologic.
That structural difference is the real basis for the capsule format, and it is a legitimate one. Small molecules with the right size, charge, and lipid characteristics can survive the gut environment and cross intestinal and cell membranes well enough to reach circulation. Several NNMT inhibitor candidates, including 5-amino-1MQ, were developed and characterized specifically as small molecules with drug-like properties in enzyme assay and animal work (Neelakantan 2018, membrane-permeable NNMT inhibitors reversing diet-induced obesity in mice; Gao 2018, small molecule NNMT inhibitor for metabolic disorders). The chemistry supports the idea that oral dosing is plausible. It does not, by itself, tell you how much of an oral capsule dose actually reaches a person's bloodstream, how long it stays active, or what dose would be needed to reproduce anything seen in mice.
What has actually been measured, and in what species
This is the part that gets flattened in most retail marketing copy. The only pharmacokinetic and oral bioavailability study identified for 5-amino-1MQ used an LC-MS/MS assay to track the compound in rat plasma after oral and other routes of administration (Vekaria 2021, oral bioavailability study in rats). That is a real, useful piece of evidence. It is also a rat study. It tells you the compound was detectable in rodent blood after oral dosing under specific experimental conditions, using specific formulations and doses that are not necessarily the same as what is in a commercial capsule.
It does not tell you:
- What the human oral bioavailability percentage is
- Whether food, gut pH variation, or formulation differences between manufacturers change absorption
- What blood concentration corresponds to meaningful NNMT inhibition in a living person
- Whether repeated daily oral dosing in humans produces stable, reproducible levels
The obesity-reversal and metabolic effects reported for 5-amino-1MQ, including the original high-fat-diet mouse work (Neelakantan 2018) and related tricyclic inhibitor follow-up studies (Gao 2022, novel tricyclic NNMT inhibitors), were also generated in mice, typically using injected or gavage-delivered compound in controlled lab conditions, not commercial oral capsules taken by free-living adults. A rodent result plus a separate rodent bioavailability study is not the same as a demonstrated human dose-response relationship. For a broader accounting of what the weight-loss evidence base does and does not show, see the weight loss evidence page.
Does capsule marketing overstate what is known?
Often, yes, in a specific and identifiable way. It is accurate to say 5-amino-1MQ is a small molecule capable of oral absorption in principle. It is not accurate to say, without qualification, that oral capsules are "clinically proven bioavailable" or that a given milligram dose reliably reproduces mouse-model effects in a person. The gap between those two statements is exactly where marketing language tends to slide from a defensible chemistry claim into an unsupported efficacy claim. Anyone evaluating dosing claims for a specific product should ask whether the dose was chosen from any human data at all, since none appears to exist in the sources reviewed here.
A verification framework: chemically plausible versus clinically confirmed
Use this table to sort any claim you encounter about 5-amino-1MQ capsules into what tier of evidence it actually belongs to, rather than accepting "orally bioavailable" as a single settled fact.
| Claim you hear | What would confirm it | What currently exists |
|---|---|---|
| "It's a small molecule, so it can be taken by mouth" | Structural analysis, membrane permeability assays | Supported: it is not a peptide and lacks peptide bonds for gut proteases to target (Neelakantan 2018) |
| "It has measured oral bioavailability" | Human PK trial with blood concentration curves | Only a rat plasma PK study exists (Vekaria 2021); no human PK data identified |
| "This dose reduces fat mass like in the mouse studies" | Human dose-ranging trial replicating the animal endpoint | No human efficacy trial identified; mouse diet-induced obesity data only (Neelakantan 2018) |
| "It's safe at this dose long-term" | Human safety and tolerability trial data | No human safety trial identified; see the safety page for what animal and mechanistic data suggest about caution |
| "It's legal to buy and use" | FDA approval, clearance, or 503A bulk listing | None of these apply; not on the 503A list and not FDA approved for any use (FDA bulk list) |
If a product page or seller answers every row of this table with confident human-level claims, that confidence is not coming from the published evidence base as it currently stands.
How does this compare with GLP-1 peptide dosing logic?
GLP-1 receptor agonists face the opposite problem: they are peptides, so oral versions require special absorption-enhancing formulations or, more commonly, injection, precisely because the gut destroys unprotected peptides. 5-amino-1MQ sidesteps that specific problem by not being a peptide at all, which is a genuine structural advantage for oral dosing. But sidestepping one obstacle (peptide bond degradation) does not automatically clear every other obstacle to reliable human absorption, metabolism, and dose-response. Readers comparing the two classes directly may find the 5-amino-1MQ versus GLP-1 comparison useful, along with the general what is 5-amino-1MQ overview for the enzyme target itself.
What is established, what is plausible, and what is not established
Established: 5-amino-1MQ is a small molecule, not a peptide, structurally distinct from injectable peptide therapeutics, and it inhibits NNMT in enzyme and cell assays (Neelakantan 2018; Gao 2018).
Plausible but unproven: that oral capsule formulations sold commercially deliver a dose to human circulation sufficient to meaningfully inhibit NNMT, given that the compound was orally detectable in rat plasma (Vekaria 2021).
Not established: human oral bioavailability percentage, an effective or safe human dose, and any human clinical outcome, metabolic or otherwise, from oral 5-amino-1MQ use.
If you are weighing whether to try a capsule product, that last category is the one to sit with. A chemically reasonable delivery route is not the same as a demonstrated one, and the honest answer right now is that nobody has published the human data needed to close that gap. Questions about sourcing and verification specific to unregulated products are addressed on the how to get 5-amino-1MQ page, and readers weighing overall confidence in this compound's evidence base should see the evidence quality overview.
If you experience unexpected symptoms after taking any unregulated compound, including gastrointestinal distress, jaundice, unusual fatigue, or signs of an allergic reaction, stop use and seek medical evaluation promptly rather than waiting to see if it resolves.